{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:12Z","timestamp":1790409252782,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41375-024-02506-1","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T10:54:19Z","timestamp":1736938459000},"page":"710-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Daratumumab plus lenalidomide\/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-4796","authenticated-orcid":false,"given":"Supratik","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-5094","authenticated-orcid":false,"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-5161","authenticated-orcid":false,"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-7140","authenticated-orcid":false,"given":"Michael","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tiab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krevvata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Borgsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2506_CR1","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M De Weers","year":"2011","unstructured":"De Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"2506_CR2","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J Lammerts van Bueren","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474.","journal-title":"Blood"},{"key":"2506_CR3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311\u201321.","journal-title":"MAbs"},{"key":"2506_CR4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking. J Immunol. 2016;197:807\u201313.","journal-title":"J Immunol"},{"key":"2506_CR5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"2506_CR6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams III","year":"2019","unstructured":"Adams HC III, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, et al. High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A. 2019;95:279\u201389.","journal-title":"Cytometry A"},{"key":"2506_CR7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HC III, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021;35:573\u201384.","journal-title":"Leukemia"},{"key":"2506_CR8","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","volume":"106","author":"M Kinder","year":"2021","unstructured":"Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, et al. Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica. 2021;106:2004\u20138.","journal-title":"Haematologica"},{"key":"2506_CR9","unstructured":"DARZALEX\u00ae (daratumumab) injection [package insert]. Horsham, PA: Janssen Biotech, Inc; 2023."},{"key":"2506_CR10","unstructured":"European Medicines Agency. DARZALEX 20 mg\/mL concentrate for solution for infusion [summary of product characteristics]. Accessed July 30, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf."},{"key":"2506_CR11","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"2506_CR12","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582\u201396.","journal-title":"Lancet Oncol"},{"key":"2506_CR13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/EDBK_320105","volume":"41","author":"J Caro","year":"2021","unstructured":"Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to treat high-risk myeloma at diagnosis and relapse. Am Soc Clin Oncol Educ Book. 2021;41:291\u2013309.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2506_CR14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867\u201374.","journal-title":"Mayo Clin Proc"},{"key":"2506_CR15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.clml.2022.03.002","volume":"22","author":"H Mian","year":"2022","unstructured":"Mian H, Reece D, Masih-Khan E, McCurdy A, Kardjadj M, Jimenez-Zepeda VH, et al. Survival and outcomes of newly diagnosed multiple myeloma patients stratified by transplant status 2007-2018: retrospective analysis from the Canadian Myeloma Research Group Database. Clin Lymphoma Myeloma Leuk. 2022;22:608\u201317.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2506_CR16","first-page":"220","volume":"1","author":"AG Szabo","year":"2019","unstructured":"Szabo AG, Iversen KF, Moller S, Plesner T. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study. Clin Hematol Int. 2019;1:220\u20138.","journal-title":"Clin Hematol Int"},{"key":"2506_CR17","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"2506_CR18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"2506_CR19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115:762\u201377.","journal-title":"Int J Hematol"},{"key":"2506_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01088-6","volume":"14","author":"A Chari","year":"2024","unstructured":"Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024;14:107.","journal-title":"Blood Cancer J"},{"key":"2506_CR21","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"2506_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109.","journal-title":"Blood Cancer J"},{"key":"2506_CR23","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","volume":"18","author":"LJ Costa","year":"2020","unstructured":"Costa LJ, Usmani SZ. Defining and managing high-risk multiple myeloma: current concepts. J Natl Compr Canc Netw. 2020;18:1730\u20137.","journal-title":"J Natl Compr Canc Netw"},{"key":"2506_CR24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2021000229","volume":"2021","author":"MV Mateos","year":"2021","unstructured":"Mateos MV, Martinez BP, Gonzalez-Calle V. High-risk multiple myeloma: how to treat at diagnosis and relapse? Hematology Am Soc Hematol Educ Program. 2021;2021:30\u201336.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2506_CR25","unstructured":"Facon T, Kumar SK, Orlowski RZ, Bahlis N, Morea P, Goldschmidt H, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA Study. Presented at: European Hematology Association (EHA) Hybrid Congress; 2024; Madrid, Spain."},{"key":"2506_CR26","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"2506_CR27","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"2506_CR28","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"2506_CR29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia"},{"key":"2506_CR30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36:1066\u201377.","journal-title":"Leukemia"},{"key":"2506_CR31","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"2506_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269\u201377.","journal-title":"Leukemia"},{"key":"2506_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"2506_CR34","unstructured":"Kumar SK, Moreau P, Bahlis N, Facon T, Plesner T, Orlowski RZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. Presented at: 64th American Society of Hematology (ASH) Annual Meeting & Exposition; 2022; New Orleans, LA, USA."},{"key":"2506_CR35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"2506_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338.","journal-title":"Lancet"},{"key":"2506_CR37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","volume":"14","author":"K Bisht","year":"2021","unstructured":"Bisht K, Walker B, Kumar SK, Spicka I, Moreau P, Martin T, et al. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021;14:1099\u2013114.","journal-title":"Expert Rev Hematol"},{"key":"2506_CR38","volume":"12","author":"H You","year":"2022","unstructured":"You H, Jin S, Wu C, Wang Q, Yan S, Yao W, et al. The independent adverse prognostic significance of 1q21 gain\/amplification in newly diagnosed multiple myeloma patients. Front Oncol. 2022;12:938392.","journal-title":"Front Oncol"},{"key":"2506_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9:94.","journal-title":"Blood Cancer J"},{"key":"2506_CR40","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11:83.","journal-title":"Blood Cancer J"},{"key":"2506_CR41","volume":"36","author":"YT Wang","year":"2022","unstructured":"Wang YT, Bao L, Chu B, Chen XH, Lu MQ, Shi L, et al. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis. J Clin Lab Anal. 2022;36:e24375.","journal-title":"J Clin Lab Anal"},{"key":"2506_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-62885-0","volume":"10","author":"M Baysal","year":"2020","unstructured":"Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H, et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep. 2020;10:5991.","journal-title":"Sci Rep"},{"key":"2506_CR43","volume":"12","author":"C Marcon","year":"2022","unstructured":"Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D, et al. Experts\u2019 consensus on the definition and management of high risk multiple myeloma. Front Oncol. 2022;12:1096852.","journal-title":"Front Oncol"},{"key":"2506_CR44","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol. 2023;41:3945\u201355.","journal-title":"J Clin Oncol"},{"key":"2506_CR45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57\u201373.","journal-title":"Lancet Oncol"},{"key":"2506_CR46","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood. 2017;130:2610\u20138.","journal-title":"Blood"},{"key":"2506_CR47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"2506_CR48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bjh.17499","volume":"194","author":"SJ Harrison","year":"2021","unstructured":"Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, Spencer A, et al. Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194:120\u201331.","journal-title":"Br J Haematol"},{"key":"2506_CR49","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","volume":"107","author":"T Martin","year":"2022","unstructured":"Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, et al. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022;107:2485\u201391.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02506-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02506-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02506-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:09:26Z","timestamp":1741086566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02506-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2506"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02506-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PM served on an advisory board for and received honoraria from Janssen, Celgene, Amgen, AbbVie, Sanofi, and Oncopeptides. TF has nothing to disclose. SZU received research funding from Amgen, Array BioPharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, and Takeda; served in a consulting role for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Edo Pharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, and TeneoBio; and served on a speakers bureau for Amgen, Bristol Myers Squibb, Janssen, and Sanofi. NB served in a consulting or advisory role for and received honoraria from AbbVie, Bristol Myers Squibb\/Celgene, FORUS, Genentech, Janssen, Karyopharm, Pfizer, Sanofi, and Takeda; and received research funding from Pfizer and Celgene. NR served as a consultant for Bristol Myers Squibb, Janssen, Takeda, Amgen, and GlaxoSmithKline; and received research funding from bluebird bio. TP served as an advisor for Janssen, Celgene, Takeda, Oncopeptides, Genentech, CSL Behring, and AbbVie; and received research support from Janssen, Genmab, Celgene, Takeda, Oncopeptides, Genentech, AbbVie, and Roche. RZO received research funding from Asylia Therapeutics, Biotheryx, Heidelberg Pharma, CARsgen, Celgene\/Bristol Myers Squibb, Exelixis, Janssen, Sanofi-Aventis, and Takeda; received honoraria from and served as a member on a board of directors or advisory committee for AbbVie, Biotheryx, Bristol Myers Squibb, Janssen, Karyopharm, Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin, Oncopeptides, Regeneron, Sanofi-Aventis, and Takeda; and holds stock in Asylia Therapeutics. SB served as a consultant and on a speakers bureau for Sanofi, Pfizer, and Bristol Myers Squibb. HN is an employee of Genmab. CH received honoraria from Janssen, Bristol Myers Squibb, Amgen, Takeda, and AbbVie. HQ served as a consultant for and received research funding from AbbVie, Bristol Myers Squibb, Karyopharm, Amgen, GlaxoSmithKline, and Antengene. HG received grants and\/or provisions of Investigational Medicinal Product from Amgen, Array BioPharma\/Pfizer, Bristol Myers Squibb\/Celgene, Chugai, Dietmar Hopp Foundation, Janssen, Johns Hopkins University, Mundipharma, and Sanofi; received research support from Amgen, Bristol Myers Squibb, Celgene, GlycoMimetics, GlaxoSmithKline, Heidelberg Pharma, Roche, Karyopharm, Janssen, Incyte, Millennium Pharmaceuticals, Molecular Partners, Merck Sharp & Dohme, MorphoSys AG, Pfizer, Sanofi, Takeda, and Novartis; served on an advisory board for Amgen, Bristol Myers Squibb, Janssen, Sanofi, and Adaptive Biotechnologies; received honoraria from Amgen, Bristol Myers Squibb, Chugai, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Pfizer; and received support for attending meetings and\/or travel from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Pfizer. MO served as a consultant for Janssen. AP received honoraria from AbbVie, Amgen, Celgene\/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Takeda; served as a member on a board or advisory committee for Amgen, Celgene\/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, and Takeda; and received research funding from Takeda. CPV received honoraria from Janssen, Bristol Myers Squibb, Sanofi, FORUS, Pfizer, AbbVie, GlaxoSmithKline, and Amgen. KW received research funding from Amgen, Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb\/Celgene, BeiGene, Janssen, GlaxoSmithKline, Sanofi, Stemline, and Takeda; received honoraria from AbbVie, Amgen, Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb\/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, and Takeda; and received travel support from Janssen, GlaxoSmithKline, and Sanofi. MT has nothing to disclose. MM served on an advisory board for Celgene\/Bristol Myers Squibb, Janssen, Takeda, Amgen, GlaxoSmithKline, and Sanofi; received research funding from Janssen and Takeda; and received accommodations from Janssen, Celgene\/Bristol Myers Squibb, Takeda, Amgen, and Sanofi. LF received honoraria from Janssen, Sanofi, Amgen, and Takeda; and received funding from Janssen and Amgen. XL received honoraria, research support, and consulting fees from Amgen, Merck, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Oncopeptides, Takeda, Roche, Novartis, AbbVie, Sanofi, Gilead, Pfizer, Harpoon Therapeutics, Regeneron, and iTeos. GW, HP, and FB are employees of Janssen and hold stock in Johnson & Johnson. MK and RC are employees of Janssen. SKK received research funding from AbbVie, Amgen, Allogene, AstraZeneca, Bristol Myers Squibb, CARsgen, GlaxoSmithKline, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron, and Molecular Templates; participated in consulting or an advisory board (with no personal payments) for AbbVie, Amgen, Bristol Myers Squibb, Janssen, Roche-Genentech, Takeda, AstraZeneca, bluebird bio, Epizyme, Secura Bio, Monte Rosa Therapeutics, Trillium, Loxo Oncology, K36, Sanofi, and Arcellx; and participated in consulting or an advisory board (with personal payments) for Oncopeptides, BeiGene, Antengene, and GLH Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}